Bulk Anti-Human CD19 (SJ25-C1) Antibody

Product Specifications

Product Name Alternative

B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12

UniProt

P15391

Host

Mouse

Reactivity

Human

Immunogen

NALM1 + NALM16 cells

Target

CD19

Isotype

IgG1 κ

Clone

SJ25-C1

Applications

Flow Cytometry

Purification Method

This monoclonal antibody was purified using Protein A

Concentration

≥ 2.0 mg/mL

Endotoxin

<0.5 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

References & Citations

Gambles, MT et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy, Nanomedicine: Nanotechnology, Biology and Medicine, Volume 67, 2025, 102825.

Shipping Conditions

Blue ice

Storage Conditions

Anti-CD19 In Vivo Antibody - Low Endotoxin (SJ25-C1) is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Specificity

Anti-CD19 In Vivo Antibody - Low Endotoxin (SJ25-C1) recognizes an epitope on Human CD19

Formulation

0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Antigen Distribution

Anti-Human CD19 recognizes a (Mr 90 kDa) B-cell surface glycoprotein which is present at all stages of maturation. Anti-CD19 does not react with T-cells, granulocytes, monocytes, erythrocytes or platelets. The CD19 antigen is expressed on approximately 5-25% of human peripheral blood lymphocytes and approximately 60% of splenic lymphocytes.